The neuroscience technology company Cambridge Cognition Holdings PLC (Cambridge, UK - LSE: COG) and research design experts Ctrl Group Limited (London, UK) are presenting the first prototype of a ground-breaking new software application to improve the understanding, diagnosis and treatment of mental health ahead of schedule on April 7 at the Neurotech Investing and Partnering Conference in Boston, MA.
Having reached prototype stage earlier than anticipated, development work will continue through a joint venture called Cognition Kit. The new products have the potential to transform healthcare and medical research in a wearable health industry estimated to be worth $2 billion and expected to surpass $40 billion by 20201. The need for more effective measures of brain health has never been greater with the World Health Organization reporting that mental ill health is now the leading causes of disability worldwide2 and the global cost of mental illness is predicted to increase to over $6T by 20303.
Cognition Kit™ technology for wearable and smart devices gathers rich physical and neurological health data during everyday life. Over time, the software learns how each individual’s mood and cognitive performance varies moment-by-moment together with the factors that contribute to their wellness, such as sleep, stress and physical activity. This understanding creates a more natural and accurate profile of a person’s mental health helping people track their wellbeing, intervene if their health declines and lead fuller, more active lives.
Ben Fehnert, Co-founder, Ctrl Group: “At Ctrl Group we believe that new technologies have the power to transform healthcare and research. Understanding and designing products for everyday lives are at the heart of our work and, through Cognition Kit, we will create mobile and wearable software tools to capture a much richer and realistic picture of an individual’s cognitive health. Intuitive and non-intrusive software can then sensitively measure and understand precise cognitive processes in real life”.
Dr Jenny Barnett, Director of Healthcare Innovation, Cambridge Cognition: “For patients with a wide range of brain health conditions, mood and cognitive performance can be an early indicator of change in their condition or response to treatment. Cognition Kit will make it easy for patients and doctors to understand how daily changes in factors like stress, sleep, and exercise effect how we feel and how well we are able to concentrate, remember and make good decisions so that we can take action earlier and better manage our own health and wellbeing”.
About Cambridge Cognition
Cambridge Cognition is a world leading provider of cognitive assessment technology, detecting the earliest signs of cognitive impairment faster, more accurately and at lower cost than other methods. The company’s CANTAB® products are validated by over 30 years of peer-reviewed research and used in pharmaceutical clinical trials to accelerate the development of safe and effective drug treatments. In addition, the company now develops and markets digital health products to monitor and maximise mental health and wellbeing throughout life. www.cambridgecognition.com.
About Cognition Kit
Cognition Kit is a collection of digital tools that makes use of mobile & wearable devices to take research out of the lab and into the daily life measuring cognition and real-time analytics to better understand mental health with richer, more meaningful data. www.cognitionkit.com
